MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789
D926FC00001
Phase 1 small_molecule active
Quick answer
MYCOPHENOLATE MOFETIL, INFLIXIMAB, Rilvegostomig, Rilvegostomig, volrustomig, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, AZD7789 for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) is a Phase 1 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active